The Wave PRO™
An innovative approach to Chronic Stable Angina
A non-invasive heart therapy designed to support patients with CSA, simplify clinical delivery, and deliver better care economics.1
Accessible ECP Therapy for Modern Care
For decades, external counterpulsation (ECP) has offered a non-invasive option for adults with Chronic Stable Angina (CSA) who are no longer candidates for revascularization. Yet legacy ECP systems have remained large, immobile, and difficult to integrate into today’s care environments—limiting patient access and creating workflow challenges for clinics and hospitals.
Wave PROTM
Wave PRO’sTM compact, automated, calf-only design makes ECP therapy more comfortable for patients1, simpler for clinicians, and easier for care systems to deploy at scale—expanding access beyond specialized centers.
A Better Experience for Every User
Patients
Clinicians
- Substantial clinical benefit demonstrated by ECP therapy in over 80% of patients with CSA2
- Minimal setup
- Automated treatment delivery
- Operates using a single fingertip sensor
- Reduces workflow complexity and hands-on time
Care Systems
- Portable, capital-efficient and reimbursable
- Small footprint, no dedicated space
- Minimal staffing requirement
- Ideal for outpatient, rehab, and community care
- Automated delivery enhances efficiency
- Durable, low-maintenance, fully warrantied
Clinically Validated Performance
Wave PRO was clinically tested under the WaveCRESST clinical trial and was shown to be equivalent to predicate ECP therapy devices, as well as showing a preference for patient comfort and less set up time with a calf-only design for care providers.1
Aligned With Established ECP Outcomes
ECP therapy has been shown to improve symptoms and functional status in over 80% of patients with drug-refractory chronic stable angina. Wave PRO delivers these therapeutic principles through an accessible, automated platform.2
How Wave PRO Works
Wave PROTM delivers external counterpulsation therapy through lightweight calf sleeves that inflate and deflate in sequence, synchronized with the heart’s resting phase1. The system uses fingertip PPG sensing and an automated timing algorithm to ensure each compression occurs at the right moment in the cardiac cycle. This simple, automated process helps support healthy blood flow back to the heart. The Wave PROTM delivers results without surgery, without recovery time, and with minimal staff involvement.
Key Features
- Pulse-synchronized compression using fingertip PPG sensing
- Calf-only sleeves with five chambers for targeted, comfortable therapy
- Automated timing algorithm
- Set up in minutes
- Automated delivery once therapy is underway
Indications & Safety
Intended Use
Wave PROTM is FDA-cleared for adults with Chronic Stable Angina that is refractory to optimal medical therapy and who are not candidates for revascularization. It is also intended for healthy adults seeking improved circulation and vascular performance.1
Safety
The Wave PROTM
is designed to be delivered safely under the supervision of trained healthcare professionals, with established protocols to support patient tolerance and clinical use.
Performance
In the WaveCRESST clinical study, Wave PROTM was well tolerated and demonstrated equivalent diastolic augmentation. Patients found Wave Pro’sTM calf-only design more comfortable.1
Experience the Next Generation of ECP Therapy
Wave PROTM makes clinically validated ECP therapy more accessible for patients and easier to deliver across modern care settings.
Footnotes:
[1] National Library of Medicine (U.S.). WAVECRESST Clinical Trial Results. ClinicalTrials.gov identifier: NCT06571370. Updated September 3, 2024. Accessed January 28, 2026. https://clinicaltrials.gov/study/NCT06571370
[2] Shah SA, Shapiro RJ, Mehta R, Snyder JA. Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis. Pharmacotherapy. 2010 Jul;30(7):639-45. https://doi.org/10.1592/phco.30.7.639.
[3] Pettersson, T., Bondesson, S., Cojocaru, D. et al. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 6, 28 (2006). https://doi.org/10.1186/1471-2261-6-28
[4] Wu, Eline MNSc, RN; Desta, Liyew PhD, MD; Broström, Anders PhD, RN; Mårtensson, Jan PhD, RN. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. The Journal of Cardiovascular Nursing 35(4):p 375-385, 7/8 2020. | https://doi.org/10.1097/JCN.0000000000000638
[5] Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. CMS Publication 100-04. Updated periodically. https://www.cms.gov/regulations-and-guidance/guidance/manuals/internet-only-manuals-ioms-items/cms018903
[6] Zuj KA, Prince CN, Hughson RL, Peterson SD. Enhanced muscle blood flow with intermittent pneumatic compression of the lower leg during plantar flexion exercise and recovery. J Appl Physiol (1985). 2018 Feb 1;124(2):302-311. https://doi.org/10.1152/japplphysiol.00784.2017.